Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study - Swain, S M; Kim, S B; Cortés, J (Lancet Oncol, 2013)
et al.